QLYS:NASDAQQualys, Inc. Analysis
Data as of 2026-06-10 - not real-time
$109.71
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Qualys, Inc. is trading at $109.71, comfortably above its 20‑day SMA ($102.3) and 50‑day SMA ($92.99) while still below the 200‑day SMA ($118.34), indicating short‑term strength but long‑term caution. Technicals are supportive – the MACD is bullish (line > signal) and the RSI sits at 64.5, suggesting momentum without immediate overbought pressure. Fundamentals are robust: a gross margin of 83%, operating margin of 35% and ROE of 38% underscore high profitability, while a forward PE of 13.3 versus an industry average of 36 points to relative cheapness. The DCF‑derived fair value of $144.75 implies the stock is modestly undervalued, though analyst consensus (median target $96) is more conservative. Recent material news – the TotalCloud solution achieving FedRAMP High Authorization – adds a regulatory win that could expand government‑sector exposure and bolster confidence.
Despite a volatile 30‑day price swing of 50% and a beta around 0.65, the company’s strong cash position, low debt, and consistent revenue growth (~10%) provide a solid defensive cushion, supporting a buy stance for investors with medium to long horizons.
Despite a volatile 30‑day price swing of 50% and a beta around 0.65, the company’s strong cash position, low debt, and consistent revenue growth (~10%) provide a solid defensive cushion, supporting a buy stance for investors with medium to long horizons.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and price above short‑term SMAs
- Positive FedRAMP High authorization news
- Strong profit margins and cash generation
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Forward PE of 13.3 vs industry 36 indicating value
- High ROE (38%) and consistent revenue growth
- Potential upside to DCF fair value of $144.75
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustainable high gross and operating margins
- Expanding government and compliance market through FedRAMP
- Strong balance sheet with ample cash and low debt
Key Metrics & Analysis
Financial Health
Revenue Growth9.80%
Profit Margin29.41%
P/E Ratio19.7
ROE37.72%
ROA13.85%
Debt/Equity9.16
P/B Ratio6.8
Op. Cash Flow$295.1M
Free Cash Flow$237.4M
Industry P/E36.0
Technical Analysis
TrendNeutral
RSI64.5
Support$84.63
Resistance$115.89
MA 20$102.30
MA 50$92.99
MA 200$118.34
MACDBullish
VolumeStable
Fear & Greed Index84.25
Valuation
Fair Value$144.75
Target Price$107.39
Upside/Downside-2.12%
GradeFair
TypeBlend
Risk Assessment
Beta0.01
Volatility50.17%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.